WO2004056335A3 - Dispositivo de liberación que contiene venlafaxina y memantina - Google Patents

Dispositivo de liberación que contiene venlafaxina y memantina Download PDF

Info

Publication number
WO2004056335A3
WO2004056335A3 PCT/CR2003/000004 CR0300004W WO2004056335A3 WO 2004056335 A3 WO2004056335 A3 WO 2004056335A3 CR 0300004 W CR0300004 W CR 0300004W WO 2004056335 A3 WO2004056335 A3 WO 2004056335A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkinson
alzheimer
memantine
release
drug
Prior art date
Application number
PCT/CR2003/000004
Other languages
English (en)
French (fr)
Other versions
WO2004056335A2 (es
Inventor
Juan A Vergez
Joaquina Faour
Marcelo A Ricci
Ana C Pastini
Original Assignee
Osmotica Costa Rica Sa
Juan A Vergez
Joaquina Faour
Marcelo A Ricci
Ana C Pastini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004056335(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Costa Rica Sa, Juan A Vergez, Joaquina Faour, Marcelo A Ricci, Ana C Pastini filed Critical Osmotica Costa Rica Sa
Priority to EP03811268A priority Critical patent/EP1595535A2/en
Priority to AU2003302147A priority patent/AU2003302147A1/en
Publication of WO2004056335A2 publication Critical patent/WO2004056335A2/es
Publication of WO2004056335A3 publication Critical patent/WO2004056335A3/es
Priority to US11/159,410 priority patent/US20060062851A1/en
Priority to US11/532,186 priority patent/US20070077301A1/en
Priority to US11/870,247 priority patent/US20080175909A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente invención provee un dispositivo osmótico que contiene venlafaxina de liberación controlada en el núcleo en combinación con una droga de liberación rápida anti-Alzheimer o anti-Parkinson en el recubrimiento externo. La memantina es utilizada como droga anti-Alzheimer o anti-Parkinson. Realizaciones particulares de la invención proveen dispositivos osmóticos que poseen perfiles de liberación predeterminados. Una realización del dispositivo osmótico incluye un recubrimiento externo que ha sido recubierto por rocío más que por compresión en el dispositivo. El dispositivo es útil para el tratamiento de la depresión en pacientes con Alzheimer y/o Parkinson. El dispositivo y el método también pueden ser utilizados para tratar o mejorar otros síntomas asociados con le enfermedad de Alzheimer, la enfermedad de Parkinson o cualquier otro desorden neurológico. Otras formas de dosificación que proveen una liberación controlada, sostenida o extendida de venlafaxina en combinación con una liberación rápida o inmediata de memantina son útiles en la invención.
PCT/CR2003/000004 2002-12-23 2003-12-19 Dispositivo de liberación que contiene venlafaxina y memantina WO2004056335A2 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03811268A EP1595535A2 (en) 2002-12-23 2003-12-19 Delivery device containing venlafaxine and memantine and use method thereof
AU2003302147A AU2003302147A1 (en) 2002-12-23 2003-12-19 Delivery device containing venlafaxine and memantine and use method thereof
US11/159,410 US20060062851A1 (en) 2002-12-23 2005-06-22 Delivery device containing venlafaxine and memantine and methods of use thereof
US11/532,186 US20070077301A1 (en) 2002-12-23 2006-09-15 Venlafaxine osmotic device formulation
US11/870,247 US20080175909A1 (en) 2002-12-23 2007-10-10 Delivery device containing venlafaxine and memantine and method of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43615602P 2002-12-23 2002-12-23
US60/436,156 2002-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/159,410 Continuation US20060062851A1 (en) 2002-12-23 2005-06-22 Delivery device containing venlafaxine and memantine and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2004056335A2 WO2004056335A2 (es) 2004-07-08
WO2004056335A3 true WO2004056335A3 (es) 2004-11-25

Family

ID=32682351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CR2003/000004 WO2004056335A2 (es) 2002-12-23 2003-12-19 Dispositivo de liberación que contiene venlafaxina y memantina

Country Status (5)

Country Link
US (2) US20060062851A1 (es)
EP (1) EP1595535A2 (es)
AR (1) AR042550A1 (es)
AU (1) AU2003302147A1 (es)
WO (1) WO2004056335A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8168209B2 (en) 2004-11-23 2012-05-01 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
AR043467A1 (es) * 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
RS20050851A (sr) * 2003-05-27 2008-04-04 Forest Laboratories Inc., Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2564187T3 (es) 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
US20100081722A1 (en) * 2008-10-01 2010-04-01 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
WO2010112221A1 (en) * 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2017106584A1 (en) * 2015-12-16 2017-06-22 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051041A1 (en) * 2000-01-13 2001-07-19 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
WO2001051035A1 (en) * 2000-01-14 2001-07-19 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
WO2002098482A2 (en) * 2001-06-01 2002-12-12 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051041A1 (en) * 2000-01-13 2001-07-19 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
WO2001051035A1 (en) * 2000-01-14 2001-07-19 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
WO2002098482A2 (en) * 2001-06-01 2002-12-12 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGOZ, ZOFÍA ET AL: "Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats", NEUROPHARMALOGIE, vol. 42, no. 8, 2002, pages 1024 - 1030, XP002903005, ISSN: 0028-3908 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168209B2 (en) 2004-11-23 2012-05-01 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8173708B2 (en) 2004-11-23 2012-05-08 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8329752B2 (en) 2004-11-23 2012-12-11 Adamas Pharmaceuticals, Inc. Composition for administering an NMDA receptor antagonist to a subject
US8338485B2 (en) 2004-11-23 2012-12-25 Adamas Pharmaceuticals, Inc. Compositions for the treatment of CNS-related conditions
US8338486B2 (en) 2004-11-23 2012-12-25 Adamas Pharmaceuticals, Inc. Methods for the treatment of CNS-related conditions
US8362085B2 (en) 2004-11-23 2013-01-29 Adamas Pharmaceuticals, Inc. Method for administering an NMDA receptor antagonist to a subject
US8426472B2 (en) 2004-11-23 2013-04-23 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8580858B2 (en) 2004-11-23 2013-11-12 Adamas Pharmaceuticals, Inc. Compositions for the treatment of CNS-related conditions
US8598233B2 (en) 2004-11-23 2013-12-03 Adamas Pharmacueticals, Inc. Method for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8283379B2 (en) 2005-04-06 2012-10-09 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8293794B2 (en) 2005-04-06 2012-10-23 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions

Also Published As

Publication number Publication date
WO2004056335A2 (es) 2004-07-08
AU2003302147A1 (en) 2004-07-14
US20080175909A1 (en) 2008-07-24
AR042550A1 (es) 2005-06-22
AU2003302147A8 (en) 2004-07-14
EP1595535A2 (en) 2005-11-16
US20060062851A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2004056335A3 (es) Dispositivo de liberación que contiene venlafaxina y memantina
WO2003028660A3 (en) Drug delivery devices and methods
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
AP1748A (en) Chronotherapeutic dosage forms.
WO2003032928A3 (en) Therapeutic composition and use
TW200738228A (en) Neramexane modified release matrix tablet
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2005096990A3 (en) Novel modification of medical prostheses
TW200509968A (en) Prevention and treatment of synucleinopathic disease
DE60212475D1 (de) Pharmazeutische Tablette und eine Verfahren zu deren Herstellung
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
WO2009086112A3 (en) Apparatus and methods for delivering therapeutic agents
HUP0203623A2 (hu) Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
WO2004084839A3 (en) Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
PL378360A1 (pl) Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju
EP1539153A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND FOR DIABETES TYPE 2
IL182135A0 (en) Liquid allergy vaccine formulation for ormucosal administration
NO20081147L (no) Marrubiin og preparat for redusering av snorking, forpakning og metode
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
PL362566A1 (en) Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
WO2005039627A3 (en) Therapeutic applications for c-peptide
HUP0402381A3 (en) Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
UY28140A1 (es) Una forma de dosificación farmaceutica que comprende venlafaxina y memantina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 11159410

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003811268

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003811268

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11159410

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP